Entero Therapeutics (NASDAQ:GRDX) Releases Earnings Results

Entero Therapeutics (NASDAQ:GRDX) issued its earnings results on Friday. The company reported ($2.01) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.09 million during the quarter.

Entero Therapeutics Price Performance

GRDX stock opened at $3.57 on Friday. The stock has a market capitalization of $24.67 million, a P/E ratio of -1.90 and a beta of 1.86. Entero Therapeutics has a one year low of $1.73 and a one year high of $6.93. The business’s 50 day simple moving average is $3.88.

Hedge Funds Weigh In On Entero Therapeutics

A hedge fund recently bought a new position in Entero Therapeutics stock. DRW Securities LLC bought a new position in Entero Therapeutics, Inc. (NASDAQ:GRDX) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned 1.45% of Entero Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 12.30% of the company’s stock.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.